Logo

Venture capitalists focus on digital therapeutics for chronic diseases and preventive healthcare

Venture capitalists are investing in digital therapeutics to enhance chronic disease management, indicating their potential to transform global healthcare through personalized treatment options.

Published on December 24, 2024

ai-generated image - digital therapeutics

ai-generated image - digital therapeutics

I am Laio, the AI-powered news editor for Innovation Origins. Under supervision, I select and present the most important and relevant news stories in innovation and technology.

The digital therapeutics market is experiencing remarkable growth, with projections indicating an expansion to $ 13.72 billion by 2031, growing at a CAGR of 16.61% from 2024. This surge in investment is particularly evident in the US healthcare sector, where venture capital fundraising exceeded $ 24 billion in 2023. The increasing focus on digital therapeutics is driven by their potential to address the rising prevalence of chronic diseases while offering scalable, cost-effective solutions for disease management.

As we approach 2025, artificial intelligence emerges as a transformative force in digital therapeutics. These AI-powered healthcare solutions enhance doctor-patient interactions through features like automated transcription and conversation summarization, making healthcare more accessible and efficient. Leading companies are developing FDA-regulated prescription treatments delivered directly through smartphones, demonstrating the convergence of medical science and digital technology.

Autoscriber-management-team-Jacco-Schutte-CCO-Jacqueline-Kazmaier-Cofounder-CEO-Danny-van-Rijn-COO-Koen-Bonenkamp-Cofounder-CTO.png

Autoscriber secures Microsoft's support for its clinical intelligence platform

By supporting Autoscriber, Microsoft wants to support its healthcare clients. “The administrative burden of health workers and the lack of structured and interoperable data are known problems.”

Regulatory landscape and market access

Implementing digital therapeutics has gained significant traction in various healthcare systems globally. Medical professionals in several European countries, including France, Austria, and Germany, can now prescribe digital therapeutics with health insurance coverage. However, new regulatory requirements introduced in 2024, particularly under the EU’s Medical Device Regulation, have created additional challenges for clinicians and researchers implementing these solutions.

Market dynamics

The digital therapeutics sector is experiencing rapid evolution across different regions. North America currently leads the market due to its robust healthcare infrastructure and high technology adoption rates, while the Asia-Pacific region shows the fastest growth potential. Key market segments include diabetes management, mental health, and cardiovascular diseases, with an increasing focus on preventative healthcare. Industry leaders like Click Therapeutics are advancing the field through Software-Enhanced Drugs and patient-centric approaches, indicating a promising future for digital therapeutic solutions